Skip to main content
Download PDF

Icariin improves cardiac function and remodeling via the TGF-β1/Smad signaling pathway in rats following myocardial infarction

European Journal of Medical Research volume 28, Article number: 607 (2023) Cite this article

Abstract

Background

Postinfarction cardiac remodeling presents a compensatory mechanism aimed at mitigating congestive heart failure. It is distinguished by progressive dilatation and hypertrophy of the ventricular chambers, fibrotic alterations, and prolonged apoptosis of cardiomyocytes. The primary objective of this study was to assess the effects of icariin on myocardial fibrosis and ventricular remodeling in rats subjected to myocardial infarction (MI).

Methods

Male Sprague‒Dawley (SD) rats were subjected to randomization and subsequently divided into distinct groups: the control group, the sham group (undergoing sham operation), the MI group (experiencing ligation of the left anterior descending artery), and the icariin group. Within the icariin group, rats were further categorized into three different dose groups based on the administered icariin dosage: the MI30 group (30 mg/kg/day), the MI60 group (60 mg/kg/day), and the MI120 group (120 mg/kg/day). Cardiac function evaluation was carried out using echocardiography. Histological examinations, including hematoxylin and eosin (HE) staining, Masson staining, and immunohistochemistry studies, were conducted 90 days after the occurrence of MI. Additionally, Western blotting was employed to assess TGF‐β1, p-Smad2, and p-Smad3 levels.

Results

The administration of icariin revealed a noteworthy enhancement in cardiac function among rats afflicted with left anterior descending coronary artery (LAD) ligation. In comparison to the icariin groups, the MI group exhibited reduced EF and FS, along with elevated LVEDD and LVESD. Furthermore, the cardiac fibrosis levels in the MI group rats exhibited a considerable increase compared to those in the icariin group. Notably, the levels of Collagen I, Collagen III, MMP2, and MMP9 were significantly higher in the MI group than in the icariin group, with evident distinctions. Moreover, the expression levels of TGF-β, IL-13, p-Smad2, and p-Smad3 were notably upregulated in the MI group compared to the icariin group.

Conclusions

In an experimental rat model of MI, the administration of icariin resulted in the amelioration of both cardiac function and remodeling processes, operating through the intricate TGF-β1/Smad signaling pathway.

Introduction

As the standard of living steadily improves, the aging population is on the rise, and myocardial infarction (MI) stands as the foremost contributor to both morbidity and mortality within the realm of cardiovascular diseases worldwide [1]. While modern reperfusion therapy serves as the most efficacious approach for diminishing infarct size and ameliorating clinical outcomes after MI, heart failure remains the primary cause of death subsequent to MI. The process of heart remodeling following MI is acknowledged as the initial phase leading toward heart failure [2, 3]. Consequently, the reversal of ventricular remodeling emerges as a highly desirable prospect for the treatment of MI. Certain angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), when administered as long-term treatment, have demonstrated the capacity to attenuate ventricular remodeling [4,5,6]. However, a significant number of patients encounter intolerance to ACEIs/ARBs due to conditions such as renal dysfunction, hypotension, or hyperkalemia, among others. Hence, there exists considerable interest in identifying novel therapeutic agents capable of enhancing ventricular remodeling, thereby addressing this pressing concern.

Myocardial fibrosis and ventricular remodeling have been identified as crucial pathological factors contributing to unfavorable outcomes following MI [7]. Of notable significance, the TGF‐β1/Smad signaling pathway exhibits a close association with both myocardial fibrosis and ventricular remodeling [8, 9]. Multiple studies have revealed that TGF-β1/Smad signaling plays a pivotal role in promoting renin–angiotensin–aldosterone system (RAAS) activation and modulating the expression of matrix metalloproteinases (MMPs) [10, 11]. Through binding to the TGF-β1 receptor on the plasma membrane, it facilitates the phosphorylation of Smad2/3, leading to their interaction with Smad4 to form a complex that translocates into the nucleus, thereby initiating gene transcription [12]. Numerous experimental investigations have demonstrated a marked overexpression of TGF-β1 in the myocardium after MI, and a noteworthy reduction in MI-induced fibrosis within the heart has been observed upon inhibition of its signaling pathway [13]. Consequently, targeting the TGF‐β1/Smad signaling pathway holds promising potential as a therapeutic strategy for addressing myocardial fibrosis and ventricular remodeling.

China has used traditional Chinese medicine (TCM) for more than 2000 years with proven curative effects, and the rapid development of the Chinese medicine industry has been attributed to China's high regard for Chinese medicines [14, 15]. Icariin is part of the Epimedium Genus of TCM [16]. Scientific investigations have highlighted a multitude of properties associated with components of Epimedium, and icariin, in particular, has exhibited anti-inflammatory, antioxidant, immunomodulating, and antitumor activities [17, 18]. Notably, in animal studies, icariin has demonstrated neuroprotective and cardioprotective effects [19, 20]. The current study delves into the exploration of icariin's potential mechanism in mitigating ventricular remodeling within an experimental rat model of MI, in pursuit of new potential therapeutic targets to prevent the progression of myocardial infarction patients towards myocardial fibrosis, ventricular remodeling, and ultimately heart failure.

Materials and methods

Animals and surgery

Adult male Sprague–Dawley (SD) rats weighing 220–300 g were procured from the Experimental Animal Center of Yunnan University College of Medicine. Prior to commencement, the study received ethical approval from the Animal Research Committee of Yunnan University College of Medicine under approval number YNU20220333. The rats were housed in a controlled environment maintained at 20 ± 2 °C with a 12-h light/dark cycle and 60% humidity. Following a 1-week acclimation period, the rats were randomly allocated to four groups: the control group, the sham group, the MI group, and the icariin group. In the icariin group, rats were administered icariin at doses of 30, 60, and 120 mg/kg/day for 14 consecutive days. Consequently, within the icariin group, the rats were further subdivided into three subgroups named MI 30, MI 60, and MI 120 based on the dosage they received. Anesthesia was induced using 1% pentobarbital sodium at a dose of 50 mg/kg through intraperitoneal injection, after which the rats were connected to an electrocardiograph. Subsequently, the rats’ neck skin was incised, and a step-by-step approach was employed to perform thoracotomy, separating the fascia layer by layer. The rats were then intubated and connected to a ventilator. MI was induced by ligating the left anterior descending coronary artery (LAD) following heart exposure. The same surgical procedure was performed in the sham operation group, with the exception of LAD coronary artery ligation. The successful induction of myocardial ischemia was further indicated by the presence of ST-segment elevation in the electrocardiography records.

Histopathological and immunohistochemical staining

Ninety days postsurgery, the rats were euthanized, and relevant samples were collected. During blood collection, heart tissues were also procured for histopathologic examination. Subsequently, the heart tissues were subjected to formalin fixation, paraffin embedding, and sectioning at a thickness of 4 μm. Hematoxylin–eosin (H&E) staining was performed on the tissue sections. TGF-β and IL-13 expression in the serum was assessed using the enzyme-linked immunosorbent assay (ELISA) method.

Masson’s trichrome staining

Collagen deposition and fibrosis were evaluated through Masson trichrome staining, employing the standard methodology. Left ventricular tissues procured from euthanized rats were subjected to fixation in 4% paraformaldehyde at 4 °C for 48 h, followed by paraffin embedding and sectioning at a thickness of 4 µm. The Masson staining assay was conducted utilizing a Masson Stain Kit (Sigma-Aldrich, Cat. No. HT15-1KT) in accordance with the provided instructions.

Immunohistochemical staining

Heart tissue sections measuring 4 μm in thickness were meticulously prepared for immunohistochemical staining, following established procedures. Subsequent to deparaffinization and tissue rehydration, a 3% hydrogen peroxide/methanol solution (provided by Tianjin Wind Boat Chemical Reagent Technology Co., Ltd) was employed to quench endogenous peroxidase activity. The sections were further subjected to incubation in a 10 mM citrate buffer solution (pH 6.0, sourced from Thermo Fisher Scientific) and subjected to antigen retrieval via autoclave sterilization. Following cooling and blocking, primary antibodies targeting collagen I, collagen III, MMP2, and MMP9 (sourced from Abcam, Cambridge, MA, USA) were applied. Subsequently, tissue sections were visualized using the 3,3′-diaminobenzidine tetrahydrochloride detection kit (BioGenex, CA, USA) and counter-stained with hematoxylin (Sigma-Aldrich).

Cell culture

The murine cell line RAW264.7, obtained from CHI Scientific Inc. (Jiangsu, China, Cat. No. 7-1115), were cultured routinely in Dulbecco's Modified Eagle's Medium (DMEM, Gibco, Cat. No. 11965-092) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich, Cat. No. F2442) and 1% penicillin–streptomycin (Gibco, Cat. No. 15140-122) at a temperature of 37 °C with 5% CO2. For cell dissociation, 0.25% trypsin and 0.02% EDTA were utilized. In the experimental procedures, cells from passages 3 to 6 were employed. Under interleukin-4 (IL-4) stimulation, RAW264.7 cells were differentiated into M2-type macrophages (M2). Cryopreservation of these cells was carried out using a solution containing 10% dimethyl sulfoxide (DMSO). The cultured RAW264.7 cells were randomly divided into distinct groups: (1) RAW264.7; (2) RAW264.7 + IL-4; (3) RAW264.7 + IL-4 + DMSO; and (4) RAW264.7 + IL-4 + icariin. The RAW264.7 group functioned as the untreated control, devoid of any pharmacological intervention. Conversely, the remaining experimental groups were subjected to distinct treatments, including the administration of 20 ng/mL recombinant IL-4 (SinoBiological, Cat. No. 51084-M08B), IL-4 in conjunction with DMSO, and IL-4 co-administered with 60 μM icariin (Aladdin, Shanghai, China, Cat. No. I141014-1 g).

Western blotting analysis

Proteins were extracted from cryopreserved cardiac tissues maintained under liquid nitrogen storage conditions, utilizing a RIPA lysis buffer. Quantification of protein concentration was carried out employing the BCA protein assay reagent kit, sourced from the Beyotime Institute of Biotechnology, Shanghai, China. In this analysis, the primary antibody concentrations employed were as follows: TGF‐β1 (1:1000, Abcam, ab215715), p-Smad2 (1:1000, Abcam, ab280888), p-Smad3 (1:2000, ab52903), and β-actin (1:1000, Abcam, ab8226). Detection of the protein bands was facilitated through the utilization of an enhanced chemiluminescence (ECL) system, with subsequent quantification being executed utilizing Image J software.

Echocardiographic studies

Cardiac echocardiography was conducted at multiple time points for the experimental rats, including baseline (before the surgical procedure), as well as 15, 30, 60, and 90 days after surgery. Before the examination, the rats were anesthetized using 3% pentobarbital sodium. The chest of each animal was shaved, and the animals were positioned in a dorsal decubitus posture. Commercially available instruments (Vivid T8, GE Healthcare, United States), M-mode, two-dimensional, and Doppler echocardiography were performed. During the echocardiographic assessments, we determined several key parameters, including the left ventricular end-diastolic diameter (LVEDD, mm), left ventricular end-systolic diameter (LVESD, mm), left ventricular shortening fraction (FS, %), and left ventricular ejection fraction (EF, %).

Statistical analysis

The data are presented as the means ± standard deviation (SD). Comparisons among multiple groups were conducted using one-way analysis of variance (ANOVA), followed by post hoc comparisons employing Tukey's multiple comparison test. GraphPad Prism 8.0 (GraphPad Software, San Diego, CA, USA) was utilized for all statistical analyses. A significance level of P < 0.05 was considered indicative of statistical significance between the groups.

Results

Icariin treatment improves left ventricular remodeling in rats with MI

Cardiac function assessment was carried out at multiple time points, including baseline and 15, 30, 60, and 90 days post-myocardial infarction (MI) surgery. Echocardiograms were utilized to quantify parameters such as LVESD, LVEDD, EF, and FS in rats. The M-mode graphs of each experimental group are presented in Fig. 1A. Comparing the MI and icariin treatment groups to the control and sham groups, a significant reduction in EF and FS, along with notable increases in LVEDD and LVESD, were observed. Nevertheless, treatment with icariin facilitated the functional recovery of postischemic hearts, as evidenced by increased EF and FS, coupled with decreased LVEDD and LVESD, relative to the MI group. Furthermore, an exploration of the impact of icariin concentration on left ventricular remodeling was undertaken. Post hoc multiple comparisons further revealed significant distinctions between the icariin treatment groups and the MI group. On the 15th day post-operation, there were no statistically significant differences in EF values among the four groups. However, on the 30th day post-operation, when compared to the MI group, the MI30, MI60, and MI120 groups receiving icariin treatment exhibited significantly elevated EF values, with respective P-values of 0.0125, 0.0275, and 0.0211. The EF values for the MI30, MI60, and MI120 groups exhibited statistically significant increases relative to the MI group on the 60th day (P < 0.05, P < 0.01, P < 0.05, respectively) and the 90th day (P < 0.01, P < 0.05, P < 0.05, respectively). Regarding the FS (Fractional Shortening) values, it is observed that the MI30, MI60, and MI120 groups all demonstrated significantly higher FS values compared to the MI group. When comparing the values on the 30th postoperative day, the respective P values were (P < 0.01, P < 0.01, P < 0.05). On the 60th day post-operation, the respective P-values were (P < 0.05, P < 0.01, P < 0.01), and on the 90th day post-operation, the respective P values were (P < 0.05, P < 0.01, P < 0.05). Similarly, at 60 and 90 days postoperatively, LVEDD and LVESD were notably higher in the icariin group compared to the MI group (P < 0.05). However, no statistically significant differences in EF, FS, LVEDD, and LVESD were observed among the three different icariin dosage groups. In conclusion, the present study demonstrated the development of cardiac dysfunction in MI rats, while icariin administration effectively ameliorated heart function.

Fig. 1
figure 1

The echocardiogram results showed a significant improvement in cardiac function in rats after icariin treatment. A M-mode echocardiography was used to capture representative images of SD rats before and after myocardial infarction (MI) in the icariin treatment group, MI group, sham group, and control group. B The left ventricular ejection fraction (EF), left ventricular fractional shortening (FS), left ventricular end-diastolic diameter (LVEDD), and left ventricular end-systolic diameter (LVESD) were subjected to comparative analysis among different MI groups receiving various dosages of icariin at 0, 15, 30, 60, and 90 days after MI. *P < 0.05, **P < 0.01

Full size image

Icariin reversed aggravation of myocardial ischemia

In this study, we examined postischemic MI and cardiac structural alterations using hematoxylin and eosin staining at the 90-day mark following coronary ligation. In the Control and Sham groups, the myocardial tissue structure in rats exhibited a dense and orderly pattern. Myocardial fibers appeared intact, without any signs of myocardial fiber rupture or infiltration of inflammatory cells (Fig. 2A, B). In the MI, MI30, MI60, and MI120 groups, disruptions in myocardial fiber integrity and disorganized arrangement of fibers were evident. Some myocardial cells showed nuclear dissolution and fragmentation, accompanied by a substantial infiltration of inflammatory cells surrounding necrotic myocardial cells. In contrast, the icariin treatment group exhibited a reduction in infarct size compared to the MI group. Additionally, it maintained a better structural integrity of myocardial fibers and reduced the infiltration of inflammatory cells (Fig. 2C-F). These results indicate that icariin effectively ameliorated the pathological changes associated with MI.

Fig. 2
figure 2

Oral administration of icariin attenuated myocardial ischemic injury and diminished the histological lesions. Representative photos of heart sections stained with H&E. A The control group, B The sham group, C The MI group, D The MI 30 group, E The MI 60 group, F The MI 120 group. (magnification, × 40; scale bar, 250 μm, with black arrows pointing to infiltrating immune cells)

Full size image

Icariin improved myocardial fibrosis

Masson's trichrome staining was utilized to visualize collagen, which is indicated by blue staining. As depicted in Fig. 3, rats with myocardial infarction exhibited notably severe myocardial fibrosis, extensive collagen deposition areas, and significant cardiac disarray remnants. In contrast, both the control and sham groups exhibited distinct myocardial tissue structures with well-arranged myocardial cells. Notably, the icariin-treated group displayed significantly less myocardial fibrosis than the MI group.

Fig. 3
figure 3

Icariin inhibited myocardial fibrosis. Masson trichrome staining revealed that the icariin group had less fibrous connective tissue than the MI group. A The control group, B The sham group, C The MI group, D The MI 30 group, E The MI 60 group, F The MI 120 group. (magnification, × 40; scale bar, 250 μm. The regions indicated by the black arrows correspond to collagen stained in blue)

Full size image

Icariin regulated the expression of TGF-β and IL-13 in ischemic tissue

Cardiac ischemia is among the most prevalent factors contributing to myocardial fibrosis. The cytokine interleukin-13 (IL-13) plays a pivotal role in inflammation and fibrosis, as well as fostering the proliferation of T-lymphocytes. In the context of fibrogenesis, transforming growth factor beta (TGF-β) operates as a crucial molecular mediator through its intracellular signaling pathways. In this study, the expression levels of TGF-β and IL-13 were utilized as indicators to assess myocyte apoptosis following MI. Additionally, blood specimens were collected at the 90-day mark postsurgery, and the serum concentrations of TGF-β and IL-13 were assessed using enzyme-linked immunosorbent assay (ELISA). The IL-13 levels (pg/ml) in the Control and Sham groups were 28.40 ± 3.89 and 26.48 ± 1.86, respectively. In the MI, MI30, MI60, and MI120 groups, the IL-13 levels were 50.22 ± 5.36, 50.40 ± 3.01, 48.67 ± 4.97, and 36.42 ± 1.99, respectively. IL-13 was significantly elevated in the MI, MI30, MI60, and MI120 groups compared to the Control and Sham groups (P < 0.0001). However, there were no statistically significant differences in IL-13 levels among the MI, MI30, and MI60 groups (see Fig. 4). In contrast, the MI120 group exhibited a significant reduction in IL-13 levels compared to the MI, MI30, and MI60 groups (P < 0.0001). Similar to the results for IL-13, the statistical analysis for TGF-β (pg/ml) revealed the following values: in the Control and Sham groups, TGF-β levels were 360.7 ± 93.55 and 303.2 ± 29.96, respectively. In the MI, MI30, MI60, and MI120 groups, the TGF-β levels were 651.3 ± 58.52, 653.4 ± 46.74, 641.8 ± 81.97, and 457.1 ± 29.62, respectively. TGF-β was significantly elevated in the MI, MI30, MI60, and MI120 groups compared to the Control and Sham groups (P < 0.0001). However, there were no statistically significant differences in TGF-β levels among the MI, MI30, and MI60 groups. In contrast, the MI120 group exhibited a significant reduction in TGF-β levels compared to the MI, MI30, and MI60 groups (P < 0.0001). These findings collectively indicate that icariin effectively inhibits myocardial fibrosis while concurrently reducing the levels of TGF-β and IL-13.

Fig. 4
figure 4

The bar graph depicts the quantitative analysis of TGF-β and IL-13, presented as the means ± SDs. Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test, ****P < 0.0001

Full size image

Icariin reduced the levels of collagen I, collagen III, MMP2, and MMP9

Collagen I and collagen III represent predominant components of the intracardiac collagen matrix. MI induced a substantial increase in the deposition of collagen types I and III, as observed in both the MI and icariin treatment groups compared to the sham group. Conversely, the sham and control groups displayed minimal evidence of collagen I and collagen III deposition. Notably, the administration of icariin effectively attenuated the levels of collagen I and collagen III (see Fig. 5A, B). Furthermore, the study also investigated the expression of matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9) proteins in various groups. MMPs are zinc-dependent endopeptidases that play a pivotal role in degrading collagen and aggrecan within the extracellular matrix (ECM). Among them, MMP2 and MMP9 are members of the matrix metalloproteinase family and are recognized for their critical involvement in processes such as cell invasion, metastasis, and angiogenesis. Angiogenesis, known as a key regenerative event, holds the potential to restore blood supply and repair cardiac function in patients with acute myocardial infarction (AMI). Immunohistochemical staining was employed to assess the expression of MMP2 and MMP9 in the ischemic myocardium. The findings unveiled increased levels of MMP2 and MMP9 in the MI group compared to the sham group. Conversely, the icariin treatment group exhibited a significant decrease in MMP2 and MMP9 levels relative to the MI group (see Fig. 5C, D). These outcomes suggest that icariin administration promotes blood perfusion recovery and fosters the formation of blood vessels in ischemic rats.

Fig. 5
figure 5

Icariin reduced the levels of collagen I, collagen III, MMP2 and MMP9. Immunohistochemical staining of collagen I (A), collagen III (B), MMP2 (C) and MMP9 (D) in heart sections. (magnification, × 40; scale bar, 250 μm)

Full size image

Icariin inhibited the fibrosis of cultured cardiac cells by suppressing the TGF-β1/Smad signaling pathway

As previously elucidated, the TGF-β1/Smad signaling pathway assumes a critical role in the pathogenesis of cardiac fibrosis. Notably, Smad2 and Smad3 serve as essential receptors during the initial stages of this signaling cascade. Upon activation by TGF‐β1, phosphorylated Smad2 (p‐Smad2) and phosphorylated Smad3 (p‐Smad3) play a key role in inducing cardiac fibrosis. To further substantiate the impact of icariin on cardiac fibrosis, RAW264.7 cells were exposed to IL-4 to induce the polarization of M2-type macrophages. In this context, the protein expression levels of TGF‐β1, p-Smad2, and p-Smad3 were assessed using Western blotting techniques. The results from Western blot analysis demonstrated a substantial increase in TGF‐β1, p-Smad2, and p-Smad3 levels in RAW264.7 cells treated with IL-4, thereby indicating the induction of fibrosis. However, following icariin treatment, a significant reduction in the expression levels of TGF-β1, p-Smad2, and p-Smad3 was observed. This observation indicates that icariin effectively suppresses cardiac fibrosis by inhibiting the TGF‐β1, p-Smad2, and p-Smad3 signaling pathways in M2-type macrophages (see Fig. 6).

Fig. 6
figure 6

Western blot analysis of TGF‐β, p-Smad2, and p-Smad3. The bar graph shows quantitative analysis of the TGF‐β, p-Smad2, p-Smad3 and β-actin proteins, and the results were normalized to the RAW246.7 group (A–C). TGF‐β, p-Smad2, p-Smad3 and β-actin protein expression in different groups was detected by Western blot (D). The data are shown as the means ± SDs, one-way ANOVA followed by Tukey's multiple comparison test, ****P < 0.0001

Full size image

Discussion

The findings presented in this study provide compelling evidence that the administration of icariin effectively mitigates cardiomyocyte fibrosis and leads to a significant improvement in cardiac function. Through its regulation of the TGF‐β/Smad signaling pathway, icariin exhibits the capacity to enhance ventricular reconstruction and inhibit myocardial fibrosis in rats with MI. Furthermore, the study indicates that icariin holds promise as a potential therapeutic target for addressing cardiac fibrosis.

In recent times, emergency thrombolysis and interventional therapy have witnessed a surge in popularity and widespread implementation. These advancements have not only improved the prognosis of patients with myocardial infarction but have also positively impacted their quality of life [21]. Although most patients achieve complete recovery, a subset may develop distressing symptoms such as chest pain, respiratory difficulties, arrhythmias, or even heart failure, necessitating hospitalization. The development and progression of ventricular dysfunction [22, 23], arrhythmias [24, 25], and unfavorable outcomes in heart failure (HF) patients are closely associated with ventricular remodeling [26]. In this regard, developing novel treatments is a problem that needs to be addressed urgently. In recent years, the relationship between TCM and cardiovascular disease has received increased attention [27,28,29]. TCM compounds are known to comprise a diverse array of Chinese medicinal ingredients that act through various targets, channels, and pathways to address diseases. Among these, icariin, the primary active ingredient derived from the Chinese herbal medicine Epimedium brevicornu Maxim, has garnered considerable interest [30, 31]. Several species of Epimedium can be used to extract it, including Epimedium sagitta, Epimedium pilose, Epimedium Wushan, and Epimedium korean. Icariin has been shown to protect the myocardium from ischemia and reperfusion in previous studies [32,33,34,35]. Icariin has a therapeutic effect on coronary heart disease, but its mechanism remains largely unclear. According to TCM principles, ventricular dysfunction and heart failure arise from Qi deficiency and blood stasis [36, 37]. In this study, icariin therapy exhibited notable improvements in LVEF and FS while concurrently reducing LVEDD and LVESD compared to the MI group. Moreover, this study sheds light on the hitherto unexplored function and mechanism of icariin in mitigating cardiac fibrosis.

The TGF-β1/Smad signaling pathway assumes a pivotal role in cardiac fibrosis and ventricular remodeling [38]. This study sought to quantify the changes in the expression levels of key molecules within the TGF-β1 signaling pathway. Notably, following MI, there was evident overexpression of TGF-β1 in the myocardium, whereas treatment with icariin resulted in a significant reduction in TGF-β1 in the ischemic myocardium. To validate this hypothesis, Western blotting was performed on M2-type macrophages induced by IL4, revealing that icariin supplementation led to decreased levels of TGF-β1 and Smad2/3. Presently, research concerning the antitumor activity of icariin has emerged as a prominent area of interest. These findings demonstrate that icariin effectively inhibits M2 macrophage polarization, signifying its potential to modulate the tumor microenvironment. Prior studies have already established icariin's ability to inhibit M2 macrophage polarization while promoting M1 macrophage polarization [18, 39]. There is still work to be done to determine whether icariin affects myocardial fibrosis and ventricular remodeling by regulating macrophage polarization.

In conclusion, the present study provides compelling evidence that icariin significantly reduces cardiac fibrosis and ameliorates cardiac function in rats with myocardial infarction. The potential protective effects of icariin are closely associated with modulation of the TGF-β1/Smad signaling pathway. However, it is essential to acknowledge certain limitations within this study. First, the follow-up period for the MI rats was relatively short, thereby precluding the observation of long-term changes in cardiac function. Second, given the intricate molecular mechanisms involved, the precise mechanisms through which icariin confers protective effects on cardiac fibrosis remain incompletely elucidated. Thus, further investigations are warranted to validate and expand upon the present findings.

Limitations of the study

Firstly, the selection of icariin dosage in our study was based on a review of pertinent literature. However, it is noteworthy that there is a dearth of dose–response investigations aimed at determining the most efficacious icariin dosage for achieving optimal outcomes. Additionally, comprehensive long-term safety evaluations for icariin treatment are presently lacking. Secondly, we did not employ TTC staining to validate the myocardial infarction's extent. Lastly, it should be acknowledged that this study was characterized by a limited sample size, an absence of power calculations, and the potential influence of uncontrolled confounding variables.

Conclusion

The findings of the current study suggest that icariin possesses the capacity to enhance cardiac function and mitigate ventricular remodeling in rats following MI. These results underscore icariin's potential as a viable therapeutic target for addressing myocardial injury and ventricular remodeling.

Availability of data and materials

All data and materials utilized in this study are accessible upon reasonable request from the corresponding author.

Abbreviations

MI:

Myocardial infarction

LAD:

Left anterior descending coronary artery

LVEDD:

Left ventricular end-diastolic diameter

LVESD:

Left ventricular end-systolic diameter

FS:

Left ventricular shortening fraction

EF:

Left ventricular ejection fraction

ACEI:

Angiotensin-converting enzyme inhibitors

ARB:

Angiotensin receptor blockers

RAAS:

Renin–angiotensin–aldosterone system

MMPs:

Matrix metalloproteinases

TCM:

Traditional Chinese medicine

ELISA:

Enzyme-linked immunosorbent assay

SD:

Sprague–Dawley

H&E:

Hematoxylin and eosin

DMSO:

Dimethyl sulfoxide;

ANOVA:

One-way analysis of variance

TGF-β:

Transforming growth factor beta

ECM:

Matrix metalloproteinases

p‐Smad2:

Phosphorylated Smad2

p‐Smad2:

Phosphorylated Smad3

LV:

Left ventricular

References

  1. Levitan EB, Muntner P, Chen L, Deng L, Kilgore ML, Becker D, et al. Burden of coronary heart disease rehospitalizations following acute myocardial infarction in older adults. Cardiovasc Drugs Ther. 2016;30(3):323–31.

    Article  PubMed  CAS  Google Scholar 

  2. Asada K, Saito Y, Sato T, Matsumoto T, Yamashita D, Suzuki S, et al. Prognostic value of natriuretic peptide levels and in-hospital heart failure events in patients with acute myocardial infarction. Circ J. 2023;87(5):640–7.

    Article  PubMed  CAS  Google Scholar 

  3. Lin MS, Wang PC, Lin MH, Kuo TY, Lin YS, Chen TH, et al. Acute heart failure with mildly reduced ejection fraction and myocardial infarction: a multi-institutional cohort study. BMC Cardiovasc Disord. 2023;23(1):272.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Park DY, An S, Attanasio S, Jolly N, Malhotra S, Doukky R, et al. Network meta-analysis comparing angiotensin receptor-neprilysin inhibitors, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors in heart failure with reduced ejection fraction. Am J Cardiol. 2023;187:84–92.

    Article  PubMed  CAS  Google Scholar 

  5. Maizels L, Wasserstrum Y, Fishman B, Segev A, Ben-Nun D, Younis A, et al. Characterization of heart failure patients with reverse left ventricular remodeling postangiotensin receptor blockers/neprilysin inhibitors therapy. ESC Heart Fail. 2022;9(3):1682–8.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Houchen E, Loefroth E, Schlienger R, Proudfoot C, Corda S, Saha S, et al. Hospitalization rates in patients with heart failure and reduced ejection fraction initiating sacubitril/valsartan or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers: a retrospective cohort study. Cardiol Ther. 2022;11(1):113–27.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Bacmeister L, Schwarzl M, Warnke S, Stoffers B, Blankenberg S, Westermann D, et al. Inflammation and fibrosis in murine models of heart failure. Basic Res Cardiol. 2019;114(3):19.

    Article  PubMed  Google Scholar 

  8. Pisklova M, Osmak G, Favorova O. Regulation of smad signaling pathway by mirnas associated with myocardial fibrosis: In silico analysis of target gene networks. Biochemistry. 2022;87(8):832–8.

    PubMed  CAS  Google Scholar 

  9. Lin P, Tong X, Xue F, Qianru C, Xinyu T, Zhe L, et al. Polystyrene nanoplastics exacerbate lipopolysaccharide-induced myocardial fibrosis and autophagy in mice via ros/tgf-beta1/smad. Toxicology. 2022;480: 153338.

    Article  PubMed  CAS  Google Scholar 

  10. Sinpitaksakul SN, Pimkhaokham A, Sanchavanakit N, Pavasant P. Tgf-beta1 induced mmp-9 expression in hnscc cell lines via smad/mlck pathway. Biochem Biophys Res Commun. 2008;371(4):713–8.

    Article  PubMed  CAS  Google Scholar 

  11. Hall MC, Young DA, Waters JG, Rowan AD, Chantry A, Edwards DR, et al. The comparative role of activator protein 1 and smad factors in the regulation of timp-1 and mmp-1 gene expression by transforming growth factor-beta 1. J Biol Chem. 2003;278(12):10304–13.

    Article  PubMed  CAS  Google Scholar 

  12. Derynck R, Zhang YE. Smad-dependent and smad-independent pathways in tgf-beta family signaling. Nature. 2003;425(6958):577–84.

    Article  PubMed  CAS  Google Scholar 

  13. Ikeuchi M, Tsutsui H, Shiomi T, Matsusaka H, Matsushima S, Wen J, et al. Inhibition of tgf-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res. 2004;64(3):526–35.

    Article  PubMed  CAS  Google Scholar 

  14. Yeh TC, Ho ST, Hsu CH, Wang JO, Kao S, Su YC, et al. Preoperative use and discontinuation of traditional chinese herbal medicine and dietary supplements in taiwan: a cross-sectional questionnaire survey. Healthcare. 2023;11(11):1605.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Luo H, Zan F, Cui J. Effect of microneedle roller on promoting transdermal absorption of crossbow-medicine liquid via transdermal administration of traditional chinese medicine and the safety of crossbow-medicine needle therapy: an experimental study. J Ethnopharmacol. 2023;317:16751.

    Article  Google Scholar 

  16. Fang J, Zhang Y. Icariin, an anti-atherosclerotic drug from chinese medicinal herb horny goat weed. Front Pharmacol. 2017;8:734.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Wu B, Feng JY, Yu LM, Wang YC, Chen YQ, Wei Y, et al. Icariin protects cardiomyocytes against ischemia/reperfusion injury by attenuating sirtuin 1-dependent mitochondrial oxidative damage. Br J Pharmacol. 2018;175(21):4137–53.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Zheng X, Li D, Li J, Wang B, Zhang L, Yuan X, et al. Optimization of the process for purifying icariin from herba epimedii by macroporous resin and the regulatory role of icariin in the tumor immune microenvironment. Biomed Pharmacother. 2019;118: 109275.

    Article  PubMed  CAS  Google Scholar 

  19. Chen HA, Chen CM, Guan SS, Chiang CK, Wu CT, Liu SH. The antifibrotic and anti-inflammatory effects of icariin on the kidney in a unilateral ureteral obstruction mouse model. Phytomedicine. 2019;59: 152917.

    Article  PubMed  CAS  Google Scholar 

  20. Hao H, Zhang Q, Zhu H, Wen Y, Qiu D, Xiong J, et al. Icaritin promotes tumor t-cell infiltration and induces antitumor immunity in mice. Eur J Immunol. 2019;49(12):2235–44.

    Article  PubMed  CAS  Google Scholar 

  21. Wang J, Meng Y, Zhang C, Lu Y, Hu C, Xu K. Delays in first medical contact to primary interventional therapy and left ventricular remodeling in st-segment elevation myocardial infarction. Ir J Med Sci. 2023. https://doi.org/10.1007/s11845-023-03283-z.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Fragasso G. Severe left ventricular dysfunction after acute myocardial infarction: a call for development of adequately targeted treatments. Am J Cardiol. 2023;200:213–4.

    Article  PubMed  Google Scholar 

  23. El Amrawy AM, Zaghloul SAE, El Sharkawy EM, Sobhy MA. Prognostic value of right ventricular diastolic dysfunction in patients with inferior st-elevated myocardial infarction. Egypt Heart J. 2023;75(1):31.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Frampton J, Ortengren AR, Zeitler EP. Arrhythmias after acute myocardial infarction. Yale J Biol Med. 2023;96(1):83–94.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Demidova MM, Rylance R, Koul S, Dworeck C, James S, Aasa M, et al. Prognostic value of early sustained ventricular arrhythmias in st-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a substudy of validate-swedeheart trial. Heart Rhythm O2. 2023;4(3):200–6.

    Article  PubMed  Google Scholar 

  26. Wang L, Du A, Lu Y, Zhao Y, Qiu M, Su Z, et al. Peptidase inhibitor 16 attenuates left ventricular injury and remodeling after myocardial infarction by inhibiting the hdac1-wnt3a-beta-catenin signaling axis. J Am Heart Assoc. 2023;12(10): e028866.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Cheang I, Liao S, Zhu Q, Ni G, Wei C, Jia Z, et al. Integrating evidence of the traditional chinese medicine collateral disease theory in prevention and treatment of cardiovascular continuum. Front Pharmacol. 2022;13: 867521.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Hao P, Jiang F, Cheng J, Ma L, Zhang Y, Zhao Y. Traditional chinese medicine for cardiovascular disease: Evidence and potential mechanisms. J Am Coll Cardiol. 2017;69(24):2952–66.

    Article  PubMed  Google Scholar 

  29. Gao Z, Li S, Shang Q, Jiao Y, Zhou X, Fu C, et al. Complex networks approach for analyzing the correlation of traditional chinese medicine syndrome evolvement and cardiovascular events in patients with stable coronary heart disease. Evid Based Complement Alternat Med. 2015;2015: 824850.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Yuan JY, Tong ZY, Dong YC, Zhao JY, Shang Y. Research progress on icariin, a traditional chinese medicine extract, in the treatment of asthma. Allergol Immunopathol. 2022;50(1):9–16.

    Article  Google Scholar 

  31. Chai Y, Ji S, Zhang G, Wu Y, Yin X, Liang D, et al. Determination of icariin in chinese traditional medicine by capillary zone electrophoresis. Biomed Chromatogr. 1999;13(5):373–5.

    Article  PubMed  CAS  Google Scholar 

  32. Ke Z, Liu J, Xu P, Gao A, Wang L, Ji L. The cardioprotective effect of icariin on ischemia-reperfusion injury in isolated rat heart: potential involvement of the pi3k-akt signaling pathway. Cardiovasc Ther. 2015;33(3):134–40.

    Article  PubMed  CAS  Google Scholar 

  33. Meng X, Pei H, Lan C. Icariin exerts protective effect against myocardial ischemia/reperfusion injury in rats. Cell Biochem Biophys. 2015;73(1):229–35.

    Article  PubMed  CAS  Google Scholar 

  34. Zhai M, He L, Ju X, Shao L, Li G, Zhang Y, et al. Icariin acts as a potential agent for preventing cardiac ischemia/reperfusion injury. Cell Biochem Biophys. 2015;72(2):589–97.

    Article  PubMed  CAS  Google Scholar 

  35. Zhang F, Hu Y, Xu X, Zhai X, Wang G, Ning S, et al. Icariin protects against intestinal ischemia-reperfusion injury. J Surg Res. 2015;194(1):127–38.

    Article  PubMed  CAS  Google Scholar 

  36. Sun S, Wei Y, Zeng X, Yuan Y, Wang N, An C, et al. Circulating cd14(+)hla-dr(−/low) myeloid-derived suppressor cells as potential biomarkers for the identification of psoriasis tcm blood-heat syndrome and blood-stasis syndrome. Evid Based Complement Alternat Med. 2020;2020:4582459.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Xing M, Luo Y, Kuai L, Ru Y, Ding X, Yan X, et al. DNA methylation expression profile of blood heat syndrome and blood stasis syndrome in tcm psoriasis. Evid Based Complement Alternat Med. 2022;2022:9343285.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Hojo Y, Saito T, Kondo H. Role of apoptosis in left ventricular remodeling after acute myocardial infarction. J Cardiol. 2012;60(2):91–2.

    Article  PubMed  Google Scholar 

  39. Song L, Chen X, Mi L, Liu C, Zhu S, Yang T, et al. Icariin-induced inhibition of sirt6/nf-kappab triggers redox mediated apoptosis and enhances antitumor immunity in triple-negative breast cancer. Cancer Sci. 2020;111(11):4242–56.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Funding

This research was supported by the Science Research Foundation of Yunnan Provincial Department of Education Project (NO. 2022J0017), Medical Reserve Talent Training Program of Yunnan Provincial Health Commission of China (NO. H-2017019), and Yunnan Provincial Program for the Cultivation of High-level Innovative Health Talent (NO. YNWR-MY-2020-024).

Author information

Author notes

  1. Ji Jia and Xing-an Zhao contributed equally to this work.

Authors and Affiliations

  1. Department of Cardiology, Affiliated Hospital of Yunnan University, Kunming, 650021, Yunnan, China

    Ji Jia, Si-ming Tao, Hua-lei Dai, Xin-jin Zhang, Ming-hua Han, Bei Yang & Yu Li

  2. Dali University, Dali, 671003, China

    Xing-an Zhao

  3. West China Hospital, Sichuan University, Chengdu, 610041, China

    Jun-wen Wang

  4. Department of Echocardiography, Affiliated Hospital of Yunnan University, Kunming, 650021, China

    Rong-liang Zhang

  5. Kunming Medical University, Kunming, 650500, China

    Jin-tao Li

Authors
  1. Ji Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xing-an Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Si-ming Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun-wen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rong-liang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hua-lei Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xin-jin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ming-hua Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Bei Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jin-tao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The study was conceptualized by Ji Jia, Xing-an Zhao, Si-ming Tao, and Jun-wen Wang. The experimentation was conducted by Ji Jia, Xing-an Zhao, Si-ming Tao, Rong-liang Zhang, and Jin-tao Li. Ji Jia, Xing-an Zhao, and Si-ming Tao made significant contributions to the data analysis and manuscript preparation. Ji Jia and Si-ming Tao performed the data analyses and authored the manuscript. Hua-lei Dai, Xin-jin Zhang, Ming-hua Han, Bei Yang, and Yu Li provided constructive discussions and assistance during the analysis process.

Corresponding author

Correspondence to Si-ming Tao.

Ethics declarations

Ethics approval and consent to participate

The ethics committee of the Animal Research Committee of the Yunnan University College of Medicine reviewed and approved the study (approval number YNU20220333).

Consent for publication

This manuscript is approved by all authors for publication.

Informed consent

Not applicable.

Competing interests

The authors declare no competing interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jia, J., Zhao, Xa., Tao, Sm. et al. Icariin improves cardiac function and remodeling via the TGF-β1/Smad signaling pathway in rats following myocardial infarction. Eur J Med Res 28, 607 (2023). https://doi.org/10.1186/s40001-023-01588-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40001-023-01588-4

Keywords

European Journal of Medical Research

ISSN: 2047-783X

Contact us